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SUMMARY. Radioreceptor binding studies were designed to localize and determine
the number of a- and /S-adrenergic receptors in the mammary gland of lactating
cows. 3H-prazosin, 3H-rauwolscine and 3H-dihydroalprenolol were used for the
regional characterization of a r , a2- and /?-adrenergic receptors by competitive
inhibition of binding of 3H-ligands with unlabelled adrenergic agonists and
antagonists. The a.x-, cc2- and /?2-adrenergic receptor subtypes could thus be
demonstrated in the regions of the teats, large mammary ducts and parenchyma.
Tissues of the teat wall, of the large mammary ducts above the gland cistern and of
the mammary parenchyma were prepared to determine the density of a1; a2- and /?-
receptors by saturation binding assays using 3H-prazosin, 3H-rauwolscine and 3H-
dihydroalprenolol respectively. Binding to high affinity sites was reversible within
minutes and saturable. Equilibrium was reached within minutes. The number of a r
and a2-adrenergic receptors decreased from the teat to the mammary ducts to the
parenchyma. Most of the a.x- and a2-adrenergic receptors were found in the teat wall,
whereas in the parenchyma a-adrenergic receptors were absent or barely detectable.
The density of /?-adrenergic receptors was similar in the teat wall and the large
mammary ducts, but much lower in the parenchyma. Thus, a.x-, a2- and /?-adrenergic
receptors were found mainly in the milk purging system and hardly at all in mammary
parenchyma. Inhibition of milk removal by a-adrenergic stimulation is possibly due
to constriction of teat wall and to constriction of the mammary ducts, whereas
enhanced milk flow after /?-adrenergic stimulation is possibly due to relaxation not
only of the teat sphincter and teat wall, but probably also of the large mammary ducts.
The sympathetic nervous system is involved in peripheral modulation of milk
removal. Milk yield was decreased during adrenalin, noradrenaline or a-specific
adrenergic agonist (a-Ag) administration. The inhibition of milk removal by the
a-Ag phenylephrine was shown to be dose-dependent (H. M. Hammon, unpublished
observations). The effects were not mediated by inhibition of endogenous oxytocin
release during milking (Lefcourt & Akers, 1984; Blum et al. 1989). Furthermore, the
inhibition of milk let-down by adrenergic drugs could be abolished by a-, but not by
/?-adrenergic blockade (Blum et al. 1989). Contraction of both teat and gland cistern
was observed using ultrasonography after a-Ag administration (Bruckmaier & Blum,
1992). Inhibition of milk removal by premilking electroshocks was abolished by
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a-adrenergic blockade (Lefcourt & Akers, 1982; Blum et al. 1989). These studies
support the notion that catecholamines mediate their inhibitory effects on milk
removal through stimulation of a-adrenergic receptors located in the bovine
mammary gland (Blum et al. 1989; Bruckmaier et al. 1991), most likely on smooth
muscle cells not only in teats, but also in mammary ducts (Ziegler & Mosimann,
1960). On the other hand, enhanced milk flow after administration of /?-adrenergic
agonists (/?-Ag) was ascribed to relaxation of the teat muscles and muscles around
milk ducts leading from the alveolar tissue to the gland cistern (Hamann, 1981;
Bruckmaier et al. 1991). Binding studies using radiolabelled adrenergic compounds
as ligands indicated the existence of both a2- and a2-adrenergic receptor subtypes
and of the /?2-adrenergic receptor subtype, most likely on smooth muscles in the wall
of the bovine teat, thus confirming radioligand binding studies on smooth muscles of
the teat (Roets et al. 1984; Roets & Peeters, 1985, 1986). Adrenergic receptor density
in the teat muscles was related to milkability of lactating cows (Roets et al. 1989).
Because previous in vivo investigations suggested a- and /?-adrenergic effects not
only in the teat, but also in other regions of the udder (Bruckmaier et al. 1991;
Bruckmaier & Blum, 1992), the goal of the present investigations was the
determination of a- and /?-adrenergic receptors not only in the teat, but also in the
region of the large mammary ducts and in the mammary parenchyma. The possible
importance of the different regions of the mammary gland for inhibition of milk
removal mediated by a-adrenergic receptors and enhancement of milk flow mediated
by /?-adrenergic receptor interaction could thus be evaluated.
MATERIALS AND METHODS
Preparation of membranes
Tissues from three regions of lactating udders were used: the muscular layer of
the teat (teat region), tissue around the gland cistern including the large mammary
ducts (duct region), and mammary parenchyma from the dorsal udder in which
mammary ducts were not visible macroscopically (parenchyma region). The material
was removed immediately after slaughter and transferred on ice. The tissues of duct
and parenchyma regions were minced into small pieces with scissors and put into ice
cold 50 mM-Tris-HCl buffer, pH 7-4. The Tris-HCl buffer used in our assays contained
6 mM-MgCl2, essential for binding of the radiolabelled ligand (Moor et al. 1988), and
1 mM-EGTA to chelate metals without affecting ligand binding (Parini et al. 1987).
Teats were prepared as described by Roets et al. (1984). Internal mucosa and
epidermis were removed, and the sphincter area of the teat was cut off and discarded.
The tissue was suspended in ~ 10-15 volumes of buffer. All subsequent manipula-
tions were carried out at 4 °C. The material was homogenized four times for 20 s at
low speed (8000 rev./min) with an Ultra-Turrax homogenizer (T 25, Janke &
Kunkel, Staufen, Germany). The homogenate was centrifuged at 500 g for 10 min;
the supernatant was passed through two layers of cheesecloth and then centrifuged
at 49000 £ and 4 CC for 30 min (Moor et al. 1988). The resulting supernatant was
decanted completely and the remaining pellet was suspended in ice cold buffer (as
above) by a motor-driven Glass-Teflon homogenizer.
The protein concentration was determined using a kit (BCA Protein Assay
Reagent; Pierce, Rockford, IL, USA) and the membrane suspension was then
adjusted to 200-300 /tg protein/100 fi\. Specific 3H-ligand binding was plotted
against protein concentration and was shown to increase with increasing membrane
protein concentration, as expected (results not shown). Protein concentration was
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kept constant (200 or 300 /tg/100 /A) throughout. While membrane suspensions used
for competitive binding assays were frozen in liquid nitrogen and stored at —80 °C,
saturation binding assays were carried out immediately after preparation of the
membrane suspension. Freezing of membranes did not affect binding as such, but
preliminary studies demonstrated some reduction in the number of binding sites (Shi
et al. 1989).
Binding studies
aj-Adrenergic receptor binding was tested by use of 3H-prazosin, a highly <xr
selective antagonist (Shi et al. 1989), a2-adrenergic receptor binding with 3H-
rauwolscine, an a2-selective antagonist (Shi et al. 1989), and /?-adrenergic binding
with 3H-dihydroalprenolol (3H-DHA), a non-selective /?-adrenergic antagonist
(Hancock et al. 1979). Saturation binding assays were performed to determine
binding capacity. Competitive binding assays with different specific unlabelled
ligands were performed to characterize the receptor subtype.
Saturation binding assays. These assays were carried out to investigate the
distribution of 3H-prazosin (n = 7), 3H-rauwolscine (n = 4) and 3H-DHA (n = 7)
binding sites in teat, duct and parenchyma regions, where n is the number of udders.
Membrane suspensions (100 /tl) were incubated with increasing concentrations of the
3H-labelled ligand with or without unlabelled ligand (50 fi\) at 37 °C for 15 min with
constant shaking to determine total and non-specific binding. All drugs were
diluted in the Tris-HCl buffer described above. The binding reaction was terminated
by adding 1 ml of ice cold buffer and the material was immediately passed through
glass fibre filters (diam. 20 mm; Whatman GF/C, Whatman International,
Maidstone ME14 2LE, UK or MN GF-3; Macherey-Nagel, Diiren, Germany), using
a vacuum filtration manifold (Holzel, Dorfen, Germany). Filters were rapidly washed
three times with 5 ml saline (9 g/1), dried and placed into plastic vials. Scintillation
cocktail (3 ml; OptiPhase 'HiSafe' I I ; FSA Laboratory, Loughborough LEU, UK)
was added and the bound 3H-activity was measured in a liquid scintillation counter
(BETAmatic, Kontron, Switzerland).
Specific binding of the 3H-ligand was calculated. For testing a:- and a2-adrenergic
receptor binding, 10 /*M phentolamine (final concentration) was used as the unlabelled
ligand (or competitor), whereas for evaluation of the /?-adrenergic receptor binding
1 /tM-( + )-propranolol (final concentration) was used as competitor. Specific binding
represented 60-95 % of the total binding depending on mammary tissue site and on
the type of the 3H-labelled ligand.
Specific binding was expressed as fmol bound 3H-ligand per mg of membrane
protein. Equilibrium binding data were plotted as a function of 3H-ligand
concentration (saturation curve). Maximal binding capacities (i?max) a n d equilibrium
dissociation constants (A'D) were calculated by a curve-fitting computer program
(Motulsky, 1987).
Competitive binding assays. These experiments were performed by incubating
membrane preparations (100/tl) with a fixed concentration of 3H-labelled ligand
(50 /tl) and a series of competitors (non-radioactive a- or /?-Ag or blocking agents) at
eight or ten concentrations. Final concentrations of 3H-prazosin, 3H-rauwolscine and
3H-DHA were 1, 5 and 2 nivi respectively. The procedures used to determine
radiolabelled binding were similar to those described for saturation binding assay but
used membrane suspensions obtained from the duct region of several udders.
Binding kinetics. 3H-ligand binding kinetics were studied using a single
concentration of the 3H-ligand under standard assay conditions at different
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incubation times. Final concentrations of 3H-prazosin, 3H-rauwolscine and 3H-DHA
were 1, 5 and 2 nM respectively. Assays with 3H-prazosin and 3H-DHA were
performed at 37 °C. Assays with 3H-rauwolscine were carried out at 25 °C to
maintain the reversibility of specific binding. In assays with 3H-prazosin and 3H-
DHA the competitor was added after 10 min of binding reaction, in assays with 3H-
rauwolscine after 6 min.
Drugs
3H-prazosin (81 Ci/mmol), 3H-rauwolscine (84 Ci/mmol) and 3H-DHA (83 Ci/
mmol) were purchased from Amersham International pic (Aylesbury HP20 2TP,
UK); (— )-noradrenaline-L-hydrogen tartrate, dopamine-HCl and (+ )-isoproterenol
from Pluka AG (Buchs, Switzerland); (+ )-propranolol from Imperial Chemical
Industries (Macclesfield, UK); ( —)-adrenalin( + )-bitartrate, ( —)-propranolol, ( + )-
propranolol, prazosin-HCl, ( —)-alprenolol hydrate, atenolol, ( — )-phenylephrine-
HC1, fenoterol-HBr, yohimbine-HCl and clonidine-HCl from Sigma (St Louis,
MO 63178, USA). Phentolamine mesylate and rauwolscine-HCl were purchased from
Research Biochemicals Inc. (Natick, MA, USA). Dihydroergocryptine and dihydro-
ergotamine were kindly donated by Sandoz AG (Basle) and clenbuterol by Bayer AG
(Wuppertal, Germany).
Solutions were prepared freshly before each assay and substances were dissolved
in Tris-HCl buffer (see above). If necessary, especially when using lipophilic agents
(rauwolscine, yohimbine or prazosin), ethanol (980 ml/1) was added to promote
dissolution. In this quantity (50 IHM final concentration in the incubation media),
ethanol does not modify binding (Roets et al. 1984).
Mathematical and statistical evaluation
For data analysis we used the GraphPAD computer program (Motulsky, 1987).
Weighted least squares curve fitting of binding values was performed to analyse
saturation and competitor displacement studies. For statistical evaluation of the
results, the SAS program package (SAS, 1990, release 6.04) was employed. Competitor
displacement and receptor density were tested for significance of difference
(P < 0-05) by means of Wilcoxon's two-sample test. All values are presented as
means+ SEM.
RESULTS
Binding kinetics
3H-prazosin, 3H-rauwolscine and 3H-DHA binding was rapid and steady state
conditions were reached within minutes (Fig. 1). There was dissociation of binding
within minutes after addition of competitors at 37 °C for 3H-prazosin and 3H-DHA,
but only at 25 °C for 3H-rauwolscine.
Competitive binding assays
The i^-values and Hill coefficients (h) for inhibition of specific 3H-prazosin
binding by adrenergic competitors are shown in Table 1. For 3H-prazosin binding the
Kt value of the unlabelled ax-antagonist prazosin was lowest while the a2-selective
antagonist yohimbine and the a2-selective agonist clonidine had ~ 1000-fold higher
Ki values than unlabelled prazosin (P < 0'05). The non-selective a-adrenergic
antagonist phentolamine and the a-adrenergic agents dihydroergotamine and
dihydroergocryptine were ~ 30-50 times less potent than unlabelled prazosin for
inhibiting binding (P < 0'05). TheiQ value of phenylephrine, an aragonist, was very
high compared with the other a-adrenergic competitors. Isoproterenol, a /?-
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Fig. 1. Binding of (a) 3H-prazosin, (6) 3H-rauwolseine and (c) 3H-dihydroalprenolol to membranes of
mammary duct tissue from the udders of three cows: # , association; O, dissociation. The competitor
was (a) 10/<M-phentolamine added at 10 min, (b) 10/tM-phentolamine added at 6 min, (c) 1/tM-
propanolol added at 10 min; total binding of the radiolabelled ligand was taken as 100%.
adrenergic agonist, displaced 3H-prazosin binding only at very high concentrations.
The order of potency for inhibition of 3H-prazosin binding was prazosin > phentol-
amine > dihydroergotamine > dihydroergocryptine > yohimbine > clonidine >
adrenalin > noradrenaline > phenylephrine > isoproterenol > dopamine. Most of
the Hill coefficients were close to one, except for phentolamine, a non-selective
a-antagonist.
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Table 1. Inhibition of specific 3H-prazosin binding by adrenergic agonists and
antagonists (competitors) on membranes of the duct region of the udder
(Values for K( and h are mean + SEM for n udders)
Competitor
Prazosin
Phentolamine
Dihydroergotamine
Dihydroergocryptine
Yohimbino
Clonidine
Adrenalin
Noradrenaline
Phenylephrine
Isoproterenol
Dopamine
a, b , c . d , e, f, g ,h \ l « ( 1 . , i .
Competitor dissociation
constant (K,), M
10±0-2x lO"9"
2-7 + 0-3 x lO"8"
5-0 ± 2-0 x lO"8"
6-2 + 1-7 x 10~8b
1-1+0-2 x 1O"60
l-3±01 x 10~6c
3-7 + 0-5 x lO"6"
6-7±0-7xl0"6e
2-2±0-3xl0"5f
8-8+l-3xlO"5g
5-l+O-4xlO-4h
I I H T V\ J~\l 1 T" / I A tVk tV^ *~\B1 O i l T"\ f» *•£"* *1 HI »"fcH
Potency ratio
10000
00370
0-0200
00161
00009
00008
00003
00001
0-0000
00000
00000
Hill coefficient
of plot (k)
0-90 ±010
0-64 ±003
0-83 ±007
0-87 ±006
0-80 ±0-04
0-84 ±011
0-80 ±009
0-79 ±003
0-79 ±004
0-91 ±008
0-87 + 0-06
«
6
5
6
6
5
5
5
5
6
5
4
Table 2. Inhibition of specific 3H-rauivolscine binding by adrenergic agonists and
antagonists (competitors) on membranes of the duct region of the udder
(Values for Kf and h are mean + SEM for n udders)
Competitor
Rauwolscine
Clonidine
Phentolamine
Yohimbine
Prazosin
Adrenalin
Noradrenaline
Phenylephrine
Dopamine
Isoproterenol
s.b.cd. e.f j \ [ e a n s without common superscript letters were significantly different (P < 0-05).
Table 3. Inhibition of specific 3H-dihydroalprenolol binding by adrenergic agonists and
antagonists (competitors) on membranes of the duct region of the udder
Competitor dissociation
constant (/f,), M
3-1+0-4X10-8"
5-2 + 0-9 xlO-8""
5-4 +3-0 x 10"8ol)
8-4+l-6xlO-8b
3-3±0-6xl0-6°
3-5 + 0-7 xlO"6 c
l-0±0-2xlO"5d
4-1 +1-6 x 10"5d
1-3 + 0-2 x 10"46
2-5 ± 0-2 x 10"4'
Potency ratio
10000
0-5960
0-5740
0-3690
00090
0-0089
00030
00008
00002
00001
Hill coefficient
of plot (h)
110±019
0-68 ±006
0-73 ±0-08
0-70 ±0-07
100 ±0-24
0-70 ±0-05
0-85 ±005
0-98 + 011
0-87 ±0-03
0-99 ±0-15
n
5
5
5
5
4
5
5
5
5
5
Competitor
(— )-Propranolol
Alprenolol
(+ )-Propranolol
Clenbuterol
( + )-Propranolol
Fenoterol
Isoproterenol
Adrenalin
Noradrenaline
Atenolol
Dopamine
a.b.c.d, e. f. g AT™.
(Values for Kt and h are
Competitor dissociation
constant (Kt), M
3-5 +0-5 x 10~9a
3-7 + 0-7 x lO"90
8-6±0-8xl0-9b
4-9 ± 0-7 x 10"80
3-2±O-5xlO-'d
4-8+1-1 x 10~7<1
9-l+2-6xlO"7d
2-2 + 0-3 x 10"6e
1-7 + 0-3 x 10"5'
3-9±l-3xlO~5f
3-8+1-9X10"48
mean + SEM for n
Potencj' ratio
10000
10000
0-4444
0-0816
00124
00084
00044
00018
0-0002
0-0001
00000
udders)
Hill coefficient
of plot (h)
0-72 ±0-08
0-91 ±013
0-98 ±0-08
0-99 ±006
1 22±013
0-94 ±0-05
0-88 ±0-03
0-86 + 014
1-24 + 0-28
0-73 ±0-08
0-95 ±010
n
5
5
5
5
5
5
5
5
5
4
4
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Fig. 2. Representative saturation plot for binding of the a-antagonist 3H-prazosin to suspensions of
membrane preparations of (a) parenchyma, (b) mammary duct and (c) teat regions of one bovine
udder: O, total binding; • , non-specific binding; A, specific binding. Each point is the mean of
triplicate determinations.
The a2-adrenergic competitors rauwolscine, clonidine, and yohimbine had low,
and similar, Kt values for displacement of specific 3H-rauwolscine binding (Table 2).
Inhibition potency of the non-selective a-adrenergic antagonist phentolamine was of
the same order of magnitude, whereas the arantagonist prazosin was about 100
times less potent than unlabelled rauwolscine for inhibition of 3H-rauwolscine
binding (P < 0-05). Displacement by isoproterenol of 3H-rauwolscine binding was in
agreement with displacement of 3H-prazosine from its binding sites. The order of
potency for inhibition of 3H-rauwolscine binding was rauwolscine > clonidine >
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Table 4. Values from saturation assays of sH-prazosin, sH-rauwolscine and 3H-
dihydroalprenolol binding on membranes of different regions of the udder
(Values are means + SEM for no. of udders shown)
Ligand
3H-prazosin
(7 udders)
3H-rauwolscine
(4 udders)
3H-DHA
(7 udders)
Region
Teat
Mammary duct
Parenchyma
Teat
Mammary duct
Parenchyma
Teat
Mammary duct
Parenchyma
Maximal binding
capacity (Bmax),
fmol/mg protein
126-4 ±25-4a
38-8+ 6-3"
7-8±3-4c
130-1 ±21-6"
23-4+ 9-4"
< 3 0
123-3±21-2"
119-1 ±21-8"
23-7±5-3b
Dissociation
constant (KD), nM
0-38 ±003
0-34 ±005
0-58 + 013
4-42 + 0-68
4-38+1-37
113 + 0-23
1-41+015
l-78±0-43
Hill coefficient
(A)
0-92 ±006
0-97 + 003
101 ±001
105 ±0-08
109 ±004
0-96 ±0001
0-97 ±001
107 ±003
a.t>.c j i e a n s without common superscript letters were significantly different between regions within ligand
(P < 0-05).
phentolamine > yohimbine > prazosin > adrenalin > noradrenaline > phenyl-
ephrine > dopamine > isoproterenol. Hill coefficients were in the same range as in
3H-prazosin binding studies.
The unlabelled non-selective /^-antagonists alprenolol and propranolol had the
lowest Kt values for specific 3H-DHA binding sites, followed by the /?2-adrenergic
agonist clenbuterol (Table 3). The /?2-agonist fenoterol and the non-selective /?-
agonist isoproterenol were about 100-fold more potent than the /^-antagonist
atenolol for inhibition of 3H-DHA binding (P < 0-05). The order of potency for
inhibition of 3H-DHA binding was alprenolol > propranolol > clenbuterol >
fenoterol > isoproterenol > adrenalin > noradrenaline > atenolol > dopamine.
Inhibition of 3H-DHA binding was investigated with different isomers of propranolol.
The order of potency was dependent on stereospecificity: (— )-propranolol > (+ )-
propranolol (P < 0-05) > (+ )-propranolol (P < 0-05; Table 3). Most of the substances
competed for 3H-DHA binding with Hill coefficients close to one, except for (— )-
propranolol and atenolol.
Saturation binding assays
The specific binding of 3H-prazosin to membrane suspensions was a saturable
process (Fig. 2). There was a decrease in the density of 3H-prazosin binding sites from
the teat region to the duct region to the parenchyma region (P < 0-05; Table 4). KD
values of the three udder regions were in the same range. Hill coefficients were all
close to one.
The specific binding of 3H-rauwolscine to membrane suspensions was a saturable
process. There was a decrease in the number of 3H-rauwolscine binding sites from the
teat to the duct region (P < 0'05; Table 4). In the parenchyma region no specific 3H-
rauwolscine binding could be measured. KD values of the teat and duct region were
in the same range. Hill coefficients were all close to one.
The specific binding of 3H-DHA was saturable for each udder region. Numbers of
binding sites for 3H-DHA were similar in the teat and duct regions, but markedly
lower in the parenchyma region (P < 0-05; Table 4). KD values of the three udder
regions were of the same order. However, iCD values for 3H-prazosin, 3H-rauwolscine
and 3H-DHA binding were significantly different (P < 0-05). All Hill coefficients were
close to one.
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DISCUSSION
Kinetic experiments demonstrated the reversibility of 3H-prazosin, 3H-
rauwolscine and 3H-DHA binding. Association of 3H-rauwolscine had to be studied
at 25 °C and an excess of unlabelled phentolamine had to be added after only 6 min
because 3H-rauwolscine binding was no longer reversible with incubation for longer
times or at 37 °C. This was surprising, because competitive binding assays with
simultaneous addition of rauwolscine and phentolamine at 37 °C caused inhibition of
3H-rauwolscine binding.
Three different adrenergic receptor subtypes (tXj, a2, /?2) could be identified by
inhibition of specific 3H-prazosin, 3H-rauwolscine and 3H-DHA binding by different
subtype-specific drugs.
From the characteristics of Scatchard and Hill plots, 3H-prazosin, 3H-rauwolscine
and 3H-DHA saturation binding indicated interaction with only a single binding site,
identified as a r , a2- and /?2-adrenergic receptor subtypes respectively. K^, values
calculated for 3H-prazosin, 3H-rau\volscine and 3H-DHA binding were significantly
different from each other. On the other hand, KD values of the same 3H-ligand for
teat, duct and parenchyma region were of the same order. Numbers of a r , a2- and
/?2-adrenergic receptors of membranes obtained from the teat region agreed well with
the results of Roets et al. (1984) and Roets & Peeters (1985, 1986). Our studies
demonstrate that there are additional regions in the bovine mammary gland
containing <Xj-, a2- and /?2-adrenergic receptors, localized in the area around the gland
cistern including the large mammary ducts. However, it is important to note that the
parenchyma region contained only very small numbers of adrenergic receptors.
Thus, adrenergic receptors were mainly present in the milk purging system of the
udder.
That a-adrenergic receptors were specifically localized on smooth muscle cells of
mammary ducts cannot be stated with absolute certainty. If we assume their
presence, several in vivo studies on inhibition of milk removal after a-Ag
administration and in stress situations may be explained. The connection between
mammary parenchyma and gland cistern may be interrupted completely or in part
by a-adrenergic receptor-stimulated smooth muscle contractions of the mammary
ducts. Although oxytocin is released (Blum et al. 1989) and may cause myoepithelial
contraction, no milk or only small amounts are transported to the gland cistern and
only milk already available in the teat and gland cistern can be removed during
milking, a view supported by studies on effects of the a-Ag phenylephrine on milk
removal and intramammary pressure before and after teat stimulation (Bruckmaier
et al. 1991). Because the number of a-adrenergic receptors in particular was very low
in mammary parenchyma, the influence of the adrenergic system on this region of the
mammary gland is probably relatively small.
It has been proposed that under stress conditions or after a-Ag administration
oxytocin may not reach the receptors of myoepithelial cells because of decreasing
blood flow to the udder due to vascular contraction after catecholamine
administration through interaction with a-adrenergic receptors in the vascular bed
(Dhondt et al. 1976; Lefcourt & Akers, 1984; Gorewit & Aromando, 1985). However,
only a very small increase of oxytocin concentration in blood is necessary to elicit
milk ejection (Schams et al. 1984). Furthermore, vasoconstriction under stress
conditions is hardly the main reason for peripheral inhibition of milk removal,
because our study demonstrated only small numbers of a- and /?-adrenergic receptors
in the mammary parenchyma. From in vivo studies (Bruckmaier et al. 1991), it also
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appears unlikely that a-Ag have an effect on the responsiveness of myoepithelial cells
to oxytocin. Because of the significantly higher density of a-adrenergic receptors in
teat tissue and the region of the large mammary ducts, peripheral disturbed milk
removal by a-Ag is primarily caused by constriction of the milk purging system of
the udder.
It has been shown that administration of /?-Ag has a favourable effect on milk
flow as a consequence of teat muscle relaxation (Bernabe & Peeters, 1980; Hamann,
1981; Vandeputte-Van Messom et al. 1986). Through interaction with the numerous
/?-adrenergic receptors in the large mammary ducts, probably localized on smooth
muscles, relaxation of the large mammarj' ducts is likely. Thus, after /?-Ag
administration, transport of milk from parenchyma tissue to the cistern is facilitated
by enlarged mammary ducts and milk withdrawal accelerated after milk ejection
(Blum et al. 1989; Bruckmaier et al. 1991). Mielke et al. (1991) have suggested the
possibility of milk ejection after administration of /?-Ag. However, lack of increased
intramammary pressure by the administration of a /?-Ag contradicts these findings
(Bruckmaier et al. 1991).
We conclude that a- and /?-adrenergic receptors are present not only in teat walls,
but also around the gland cistern and large milk ducts. Thus, the modulation of milk
ejection and milk removal by the adrenergic system occurs not only during the milk's
passage through the teat cavity, but also very probably during its passage from
gland parenchyma to the gland cistern.
These studies have been supported by the Swiss National Science Foundation
(Grant no. 32-28781.90).
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